FURTHER: Xiuning Le, MD, PhD, Shares Firmonertinib Update at IASLC World Conference on Lung Cancer
2:05
FURTHER: Xiuning Le, MD, PhD, Shares Firmonertinib Update at IASLC World Conference on Lung Cancer
IASLC World Conference on Lung Cancer: Dr. Jänne on Receiving the 2025 Adi F. Gazdar Merit Award
2:16
IASLC World Conference on Lung Cancer: Dr. Jänne on Receiving the 2025 Adi F. Gazdar Merit Award
IASLC World Conference on Lung Cancer: Dr. Gerber on the Landscape of ALK+ NSCLC in the E4512 Trial
3:04
IASLC World Conference on Lung Cancer: Dr. Gerber on the Landscape of ALK+ NSCLC in the E4512 Trial
FDA Approves Subcutaneous Formulation of Pembrolizumab: What it Means for Patients With Lung Cancer
2:02
FDA Approves Subcutaneous Formulation of Pembrolizumab: What it Means for Patients With Lung Cancer
Updates in ALK+ NSCLC: Panel Reflects on New Data From the IASLC World Conference on Lung Cancer
4:01
Updates in ALK+ NSCLC: Panel Reflects on New Data From the IASLC World Conference on Lung Cancer
Survivorship in ALK+ NSCLC: Helping Younger Adults Navigate Life After Treatment
3:59
Survivorship in ALK+ NSCLC: Helping Younger Adults Navigate Life After Treatment
What Comes After Surgery: Grappling With Treatment Duration, Monitoring, and Fear of Recurrence
8:05
What Comes After Surgery: Grappling With Treatment Duration, Monitoring, and Fear of Recurrence
Patient-Centered Care in Early-Stage ALK+ Lung Cancer: Balancing Efficacy, Toxicity, and Lifestyle
10:34
Patient-Centered Care in Early-Stage ALK+ Lung Cancer: Balancing Efficacy, Toxicity, and Lifestyle
Communicating Dose Holds and Reductions in Targeted Therapy for ALK+ NSCLC
4:20
Communicating Dose Holds and Reductions in Targeted Therapy for ALK+ NSCLC
How to Recognize, Address Neurocognitive Changes in Patients Undergoing ALK Inhibitor Therapy
6:21
How to Recognize, Address Neurocognitive Changes in Patients Undergoing ALK Inhibitor Therapy
From Lab Values to Body Image Concerns: What to Watch for in Patients With ALK+ NSCLC
11:03
From Lab Values to Body Image Concerns: What to Watch for in Patients With ALK+ NSCLC
Communication as Care: How Nurse-Led Education Helps Patients With ALK+ NSCLC Manage Toxicities
5:19
Communication as Care: How Nurse-Led Education Helps Patients With ALK+ NSCLC Manage Toxicities
Extending Survival and Expanding Options: The Evolving Treatment Landscape for ALK+ NSCLC
6:46
Extending Survival and Expanding Options: The Evolving Treatment Landscape for ALK+ NSCLC
Eric Singhi, MD, Shares Highlights of IASLC World Conference on Lung Cancer
4:43
Eric Singhi, MD, Shares Highlights of IASLC World Conference on Lung Cancer
Dr. Olazagasti and Dr. Rodriguez Reflect on the IASLC World Conference on Lung Cancer
7:03
Dr. Olazagasti and Dr. Rodriguez Reflect on the IASLC World Conference on Lung Cancer
Treatment for Early-Stage ALK+ NSCLC: Updates From the IASLC World Conference on Lung Cancer
5:59
Treatment for Early-Stage ALK+ NSCLC: Updates From the IASLC World Conference on Lung Cancer
The IASLC World Conference on Lung Cancer: Dr. Girard on Unmet Needs With Second-Generation ALK TKIs
3:20
The IASLC World Conference on Lung Cancer: Dr. Girard on Unmet Needs With Second-Generation ALK TKIs
New Data and Developments in ALK+ NSCLC: Dr. Culver Shares Insights at IASLC 2025 WCLC
3:48
New Data and Developments in ALK+ NSCLC: Dr. Culver Shares Insights at IASLC 2025 WCLC
ARROS-1: Dr. Drilon Shares Zidesamtinib Data at IASLC World Conference on Lung Cancer
5:32
ARROS-1: Dr. Drilon Shares Zidesamtinib Data at IASLC World Conference on Lung Cancer
FLAURA2 Shows OS Benefit: Dr. Jänne Shares Insights at IASLC World Conference on Lung Cancer
3:13
FLAURA2 Shows OS Benefit: Dr. Jänne Shares Insights at IASLC World Conference on Lung Cancer
The Phase 3 FLAURA2 Trial: Final OS Results Detailed at IASLC World Conference on Lung Cancer
6:36
The Phase 3 FLAURA2 Trial: Final OS Results Detailed at IASLC World Conference on Lung Cancer
The Phase 3 E4512 Trial in ALK+ NSCLC: Insights From the IASLC WCLC Plenary
7:58
The Phase 3 E4512 Trial in ALK+ NSCLC: Insights From the IASLC WCLC Plenary
The Phase 3 HARMONi Trial: Dr. Le Shares Insights at IASLC World Conference on Lung Cancer
1:55
The Phase 3 HARMONi Trial: Dr. Le Shares Insights at IASLC World Conference on Lung Cancer
The IASLC World Conference on Lung Cancer: Dr. Singh on Collaborative Opportunities, Key Data
3:53
The IASLC World Conference on Lung Cancer: Dr. Singh on Collaborative Opportunities, Key Data
The IASLC World Conference on Lung Cancer: Dr. Antonoff Reflects on Significance, Highlights
7:15
The IASLC World Conference on Lung Cancer: Dr. Antonoff Reflects on Significance, Highlights
Data to Watch at the IASLC World Conference on Lung Cancer: Eric Singhi, MD, Shares Insights
5:38
Data to Watch at the IASLC World Conference on Lung Cancer: Eric Singhi, MD, Shares Insights
The IASLC World Conference on Lung Cancer: Dr. Olazagasti Previews Upcoming Meeting
6:22
The IASLC World Conference on Lung Cancer: Dr. Olazagasti Previews Upcoming Meeting
The IASLC World Conference on Lung Cancer: Dr. Liu on Highly Anticipated NSCLC Presentations
4:15
The IASLC World Conference on Lung Cancer: Dr. Liu on Highly Anticipated NSCLC Presentations
The IASLC 2025 World Conference on Lung Cancer: Dr. Antonoff on Data to Look Forward to in NSCLC
2:42
The IASLC 2025 World Conference on Lung Cancer: Dr. Antonoff on Data to Look Forward to in NSCLC
Drug Discovery in Small Cell Lung Cancer: Triparna Sen, PhD, on New Developments and Data
3:37
Drug Discovery in Small Cell Lung Cancer: Triparna Sen, PhD, on New Developments and Data